Beschorner R, Psaras T, Meyermann R, Bremer J, Schmidt T, Mittelbronn M, Schittenhelm J
Institute for Brain Research, Tübingen, Germany.
Clin Neuropathol. 2011 Jan-Feb;30(1):33-40. doi: 10.5414/npp30033.
The erythropoietin receptor (EpoR) is expressed widely throughout the human CNS, including the choroid plexus. Recent studies have shown that EpoR is also expressed in various human tumors, including carcinomas, meningiomas and gliomas. Thereby, the Epo-EpoR pathway plays a role in inhibition of apoptosis and tumor growth, infiltration, angiogenesis and metastasis as well as treatment resistance and is a potential target in oncological treatment. Lower levels of EpoR have been associated with shorter survival in high grade gliomas and higher risk of tumor recurrence in meningiomas.
Since the EpoR status in human choroid plexus tumors (CPT) is not known, we investigated 57 CPT from 43 cases including 14 recurrent tumors and compared them with 23 samples of normal choroid plexus (CP). CPT samples consisted of choroid plexus papillomas/CPP (n = 41), atypical CPP (n = 15) and choroid plexus carcinoma/CPC (n = 1). EpoR expression was determined by immunohistochemistry using semi-quantitative scoring for staining intensity and was validated in exemplary cases using western blot and RT-PCR.
EpoR expression was observed in all samples of normal and neoplastic CP with significantly lower expression levels in CPT (p < 0.001).
No significant correlation was found between EpoR expression and age, gender, WHO grade, number of mitosis or tumor recurrence. EpoR expression in CPT is in line with its expression in normal CP and with previous reports on EpoR expression in other glial neoplasms. Association of EpoR levels in CPT with survival, as known in astrocytic gliomas, remains to be determined.
促红细胞生成素受体（EpoR）在包括脉络丛在内的整个人类中枢神经系统中广泛表达。最近的研究表明，EpoR也在包括癌、脑膜瘤和神经胶质瘤在内的各种人类肿瘤中表达。因此，Epo-EpoR途径在抑制细胞凋亡、肿瘤生长、浸润、血管生成和转移以及治疗抵抗中发挥作用，并且是肿瘤治疗中的一个潜在靶点。EpoR水平较低与高级别神经胶质瘤的生存期较短以及脑膜瘤的肿瘤复发风险较高相关。
由于人类脉络丛肿瘤（CPT）中的EpoR状态尚不清楚，我们研究了来自43例患者的57个CPT，包括14个复发性肿瘤，并将它们与23个正常脉络丛（CP）样本进行比较。CPT样本包括脉络丛乳头状瘤/CPP（n = 41）、非典型CPP（n = 15）和脉络丛癌/CPC（n = 1）。通过免疫组织化学使用半定量评分来确定染色强度，从而测定EpoR表达，并在示例性病例中使用蛋白质免疫印迹法和逆转录-聚合酶链反应进行验证。
在正常和肿瘤性CP的所有样本中均观察到EpoR表达，CPT中的表达水平显著较低（p < 0.001）。
未发现EpoR表达与年龄、性别、世界卫生组织分级、有丝分裂数或肿瘤复发之间存在显著相关性。CPT中的EpoR表达与其在正常CP中的表达以及先前关于EpoR在其他神经胶质肿瘤中表达的报道一致。CPT中EpoR水平与生存期的关联，如在星形胶质细胞瘤中所知，仍有待确定。
